The world (at least the very small part of it that I inhabit) has been buzzing about Wal-Mart’s announcement that it will be pricing almost 300 generic drugs at $4 for a 30 day supply. Newspapers, private equity firms, PBMs, drug manufacturers, insurers, policy makers, and politicians are all rambling on about the various significant impacts this will have on the world, among them improving the lives of the uninsured.
I don’t get it.
Continue reading Wal-Mart’s $4 drugs – much ado about not much


